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Abstract: Ethionamide (ETH) is an important second-line antituberculosis drug used for the treatment of patients infected with 
multidrug-resistant Mycobacterium. Although ETH is a structural analogue of isoniazid (INH), both are pro-drugs that need to be acti-
vated by mycobacterial enzymes to exert their antimicrobial activity. ETH mechanism of action is thought to be identical to INH al-
though the pathway of activation is distinct from that of INH. ETH is activated by an EthA enzyme, leading to the formation of an S-
oxide metabolite that has considerably better activity than the parent drug. This review comprehensively examines the aspects related 
with the metabolism of ETH since its discovery up to today.  
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INTRODUCTION 
 Tuberculosis is an infectious disease caused by the bacillus M. 
tuberculosis and is still a world health problem of staggering pro-
portions. About one-third of the world's population is infected with 
M. tuberculosis without exhibiting symptoms of the disease. This 
airborne disease typically affects the lungs, but can also affect other 
sites of the body. Although only a relatively small proportion of 
people infected with M. tuberculosis will go on to develop tubercu-
losis disease, in the case of people infected with the human immu-
nodeficiency virus (HIV) the probability of developing tuberculosis 
is rather high. Tuberculosis is generally thought to develop in an 
individual as a consequence of one of three processes: progression 
of primary infection, exogenous reinfection, or endogenous 
reactivation [1-3]. 
 In 1993, the World Health Organization (WHO) declared tuber-
culosis a global public health emergency. According to the 2011 
WHO report [1, 2], there were 8.8 million incident cases of tubercu-
losis in 2010, 1.1 million deaths from tuberculosis among HIV-
negative people and an additional 0.35 million deaths from HIV-
associated tuberculosis. In the same year, there were 5.7 million 
notifications of new and recurrent cases of tuberculosis. A large 
effort has been put forward in several countries to fight against this 
disease and the estimated investment for treatment in 97 countries 
with 92% of the world’s tuberculosis is expected to be USD 4.4 
billion in 2012 [1]. Tuberculosis is spread from person to person 
through the air. When a person with lung tuberculosis coughs, 
sneezes or spites, the tuberculosis germs propel into the air. A per-
son needs to inhale only few of these germs to become infected [1].  
 The first line drugs normally employed to treat tuberculosis 
drug resistance are isoniazid (INH), ethambutol, pyrazinamide and 
rifampin [3]. When the infection is unresponsive to the treatment 
with first line drugs, second line drugs come into play. Because of 
the emergence of multidrug-resistant (MDR) strains of M. tubercu-
losis, second-line drugs such as ethionamide (ETH) have become 
increasingly important as replacements for INH and rifampicin, 
although ETH is relatively weak tuberculosis drug with usual  
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treatments that can last over 2 years with several side effects [4], as 
opposed to 6–9 months with INH and rifampin-containing regimens 
[5].  
 ETH is a prodrug that must undergo metabolic activation to 
exert its cytotoxic effects. ETH (1, Fig. (1)) was first used in the 
chemotherapy of tuberculosis in the early 1950’s. The feature that 
distinguishes structurally and classifies this drug is the presence of 
a thioamide function. It was recognized that S-oxygenation of the 
thiourea moiety of ETH was involved in the bioactivation of a he-
patotoxic metabolite [6], in a similar manner to what had been 
shown earlier for thiocarbamides [7]. This S-oxygenation also de-
termines the therapeutic efficacy of ETH. Ten years later ETH pro-
pyl analogue, prothionamide, PTA (2, Fig. (1)), was introduced into 
clinical treatment because it was shown in vitro to be as active as 
ETH against M. tuberculosisin contrast to the experimental tuberculo-
sis in the mouse, but appeared to be better tolerated by patients [8, 9]. 
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Fig. (1). Chemical structure of ETH (1), PTA (2) and INH (3). These pro-
drugs have similar structures but INH is activated by a catalase-peroxidase, 
whereas ETH and PTA are activated by a flavin-dependent monooxygenase 
(FMO). 
 
 These drugs have been used in the treatment of mycobacterial 
infections of M. leprae and M. avium [10, 11]. They are the most 
frequently used drugs for the treatment of drug-resistant tuberculo-
sis and, therefore, are becoming increasingly relevant as the number 
of MDR and extensively drug-resistant cases is increasing world-
wide [12, 13]. ETH and PTA are structurally similar to INH (3, Fig. 
(1)), which has been successful in the treatment of tuberculosis 
infection in the past. INH is an antibacterial drug that has been used 
to both prevent and treat tuberculosis since 1952. INH should be 
part of the treatment for all persons with tuberculosis unless there is 
a compelling reason to omit it, such as allergy to the pharmacologic 
agent. There are currently ten drugs with FDA approval for the 
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treatment of tuberculosis and the first-line agents that form a four-
drug regimen for treatment of active tuberculosis are INH, rifampin, 
ethambutol and pyrazinamide [14].  
 However, in recent history, poor compliance with the prolonged 
and complicated chemotherapeutic regimens currently used to treat 
tuberculosis, in conjugation with the advent of the AIDS epidemic 
and the increased mobility of human populations, has led to the 
emerging of numerous MDR M. tuberculosis strains [15, 16]. Re-
sistance to frontline therapeutics, such as INH, results in the treat-
ment of patients with “second-line” agents that are less effective 
and/or more toxic [17]. One of the most effective in the treatment of 
tuberculosis is ETH. 
 For 25 years, the main research involving ETH was focused on 
the type of metabolites formed [18-28], starting, thus, the study of 
ETH metabolism. During this period the principal metabolite identi-
fied was ethionamide sulphoxide (4, Fig. (2)). In recent years, the 
studies involving the pharmacokinetics (PK) of ETH are more 
complete and accurate. As an example, a study of the absorption 
and elimination of ETH  in  twelve  healthy,  adult  male volunteers 
after administration of oral tablets and rectal suppositories can be 
mentioned [29]. Treatments compared 250-mg ETH tablets and a 
placebo suppository to a 500 mg ETH suppository and two placebo 
tablets, given 7 days apart. In this study, the area under serum con-
centration-time curve was used to determine the relative bioavail-
ability of drug from preparations. The relative bioavailability after 
rectal administration was 57.3% of that after oral administration. 
The maximum concentration after rectal administration was 33% of 
that after oral administration. 
 Auclair et al. reported the effect of food, orange juice, or 
antiacids on the absorption of a single oral 500-mg dose of ETH in 
healthy volunteers, including the bioequivalence assessment, and 
determined the ETH population PK parameters [30]. The PK be-
haviour of ETH was not significantly modified by the different 
conditions studied. Mean ratios for area under curve (AUC) ranged 
from 0.91 to 0.96 for the orange juice, food, and antiacid treat-
ments, indicating a minimal effect on the relative bioavailability. 
ETH can be administered with food if tolerance is an issue [30]. 
 The PK parameters of ETH were also determined following 
oral doses. ETH PK parameters were independent of age, weight, 
height, gender, and creatinine clearance [31]. Tuberculosis patients 
appeared to have lower volumes of distribution (3.22 L/Kg) and 
clearance values (1.88 L/h/Kg) compared to healthy volunteers 
(Table 1). Therefore, this resulted in lower AUC values (3.95 mcg 
h/mL) in the tuberculosis patients. ETH displayed a short elimina-
tion half-life (1.94 h). 
 In the second-line therapy for drug-resistant tuberculosis, ETH 
should be administered with other agents due to the rapid resistance 
development when the drug is used as monotherapy. The PK pa-
rameters of ETH are given in Table 1. PK parameters differed be-
tween healthy subjects and tuberculosis patients, resulting in a 
lower AUC for tuberculosis patients, possibly due to a decrease in 
bioavailability [13, 31]. 
Table 1. PK Parameters of ETH in Humans 
Half-
life 
(h) 
AUC 
(mg.h/L) 
Cmax 
(μg/mL) 
Volume of 
distribution 
(L/Kg) 
PK methodology 
1.94 7.67 2.16 
93.5 
(sugar coated 
tablets) 
Mean PK for 250 
mg oral dose using 
film-coated tablets 
in healthy adults 
(FDA label) 
 
FROM THE PRINCIPAL METABOLITE TO THE UNDER-
STANDING OF ETH METABOLISM 
Activation of ETH 
 The link between the ETH-resistant tuberculosis and mutations 
in the Rv3855 and Rv3854c genes clearly indicates that the oxida-
tion of ETH-SO catalyzed by FAD-containing enzyme is critical for 
the activation of the drug to its cytotoxic metabolite [32, 33]. This 
provided information on the catalytic and physical properties of this 
enzyme, and demonstrated that the catalyzes in the activation of 
ETH occurs in two steps rather than in one step.  [17].  
 As a result of the oxidation of ETH by EtaA the S-oxide is 
formed (4, Fig. (2)) [17, 33], which is a metabolite that is known to 
retain the full antituberculosis activity of ETH [33]. Further oxida-
tion of the S-oxide then produces the unstable sulfinic acid and, 
eventually, the 2-ethyl-4-carboxamidopyridine metabolite that has 
no antimycobacterial activity [17, 34]. Therefore, the active me-
tabolite of ETH lies between the S-oxide and 2-ethyl-4-carbo-
xamidopyridine and might be the sulfinic acid or a product of its 
decomposition [35]. However, the sulfinic acid has not been iso-
lated yet. The activation of ETH by the M. tuberculosis EtaA was 
also extended to other related compounds [36], such as thiacetoa-
zone, PTA and isoxy (4,4-diisoamyloxydiphenyl-thiourea) [37-39]. 
Magic angle spinning NMR studies in living mycobacterial cells on 
the EtaA-dependent oxidation of ETH have shown that the forma-
tion of the S-oxide and 4-pyridylmethanol metabolites are formed 
primarily outside the cells, and the accumulation of a unidentified 
activated intermediate formed inside the cells [40, 41]. 
ETH Metabolites  
 ETH, like INH, is thought to be a prodrug that must be con-
verted to its active form by the bacterial cell. In vivo mammalian 
and bacterial studies suggested that the first metabolite of ETH is 
the thioamide S-oxide (ETH-SO, 4, Fig. (2)), which retains the 
biological activity of the parent drug [17, 33, 42]. Other metabolites 
identified in the whole cell bacterial systems include the ETH ni-
trile (5, Fig. (2)), ETH amide (6, Fig. (2)) and ETH alcohol (7, Fig. 
(2)) [17, 33]. 
 
Fig. (2). Structures of metabolites of the ETH: (4), ETH S-oxide; (5), 2-
ethyl-4-cyanopyridine; (6), 2-ethyl-4-amidopyridine; and (7), 2-ethyl-4-
hydroxymetylpyridine. 
 
 De Barber et al. postulated that ETH is activated via the corre-
sponding S-oxide (4) to a sulfinate that can form an analogous al-
dehyde equivalent (an imine) through a radical intermediate (see 
Fig. (3)). Hydrolysis of this imine could be followed by reduction 
of the resulting aldehyde to the metabolite alcohol, confirmed and 
identified as 7 by chromatography with a synthetic characterized 
alcohol standard [33]. 
 A wide variety of toxic thiocarbonyl-containing compounds 
have been shown to be converted to the corresponding S-oxides 
during in vivo metabolism by mammals supporting this intermedi-
ate oxidation in the metabolic activation of ETH [43]. 
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Fig. (3). Proposed activation process for the thioamide oxidation of ETH 
[33]. In vivo production of (2-ethyl-pyridin-4-yl) methanol (7) from ETH by 
whole cells of M. tuberculosis.  
 
 ETH-SO is not very reactive and, thus, it can be stored and 
physically characterized. The properties of ETH-SO, along with the 
observation that it is as lethal to the tuberculosis bacilli as ETH, 
suggested that ETH-SO itself requires further activation to a final 
cytotoxic species [32]. Incubation of authentic ETH-SO with ETH 
under turnover conditions shows, indeed, that it is further metabo-
lized by the enzyme to another metabolite [9]. Chromatographic 
data of this second metabolite with synthesized standards identified 
it as 2-ethyl-4-amidopyrydine (6, Fig. (2)). This second metabolite 
is thus a product of the enzymatic action of ETH on ETH-SO 
(14) and not a branching product stemming from an alternative 
reaction with ETH [17]. However, 6 is likely not the actual enzy-
matic product of ETH and ETH-SO but rather is a more stable 
molecule resulting from the decomposition of this putative cyto-
toxic metabolite, possibly a sulfinic acid specie (8, Fig. (4)). 
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Fig. (4). Possible formation of ETH amide (6) via a sulfinic acid (8). The 
ETH amide has no antitubercular activity. 
 
 Cell incubations of M. tuberculosis with radiolabelled ETH 
have indicated that ETH-SO and ETH nitrile (5) are initially formed 
and accumulated to a maximum concentration over a couple of 
hours [33]. Following this early concentration increase, ETH-SO 
and 5 concentrations begin to decrease, and an increase in the ETH 
amide (6) and ETH alcohol (7) amounts are observed [33].  
ETH Metabolism  
 To understand the ETH metabolism it is essential to cite the 
work of Johnsson et al., who suggested that this drug could be me-
tabolized to a higher S-oxide capable of undergoing addition reac-
tions to the nucleophilic protein side chain [44]. The experiments 
suggested for the first time a molecular mechanism of action, where 
ETH was activated by unidentified mycobacterial enzymes [44]. 
After that, two works were reported and explained the ETH activa-
tion [32, 33]. Firstly, it was demonstrated that overproduction of 
Rv3855 (EthR), a putative regulatory protein from M. tuberculosis, 
confers ETH resistance whereas overproduction of an adjacent, 
clustered monooxygenase (Rv3855c, EthA) confers ETH hypersen-
sitivity [33]. The production of EthA appears to be negatively regu-
lated by EthR and correlates directly with [
14
C]-ETH metabolism, 
suggesting that EthA is the activating enzyme responsible for 
thioamide oxidation and subsequent toxicity [33]. 
 In another work, it was reported the identification of an activa-
tor for ETH. The ETH activator Rv3854c (EthA) was found to be 
homologous to various monooxygenases and induced ETH sensitiv-
ity when overexpressed in mycobacteria [32]. Also, the neighbour-
ing open reading frame (Rv3855), which was found homologous to 
transcriptional repressors of the TetR family, led to ETH resistance 
when overexpressed. In addition, chromosomal inactivation of this 
gene by transposition led to ETH hypersensitivity. These data sug-
gested that Rv3855 (EthR), regulates the production of EthA, which 
subsequently activates the pro-drug ETH [32]. 
 After the identification of the ability of EthA-enzyme to acti-
vate the drug, it was reported that mutations within EtaA structural 
genes were associated with relatively high levels of ETH resistance, 
i.e. approximately 76% of isolates resistant to > 50 μg/mL of ETH 
had such mutations [45]. 
 Vannelli et al. reported that the enzyme EthA (Rv3854c code) 
is a flavoprotein containing a single FAD group that catalyzes the 
NADPH- and O2-dependent monooxygenation of ETH to the corre-
sponding S-oxide (4) [17]. The S-oxide which has a similar biologi-
cal activity as ETH, is further oxidized by EthA to 2-ethyl-4-
amidopyridine (6). This flavoenzyme also oxidizes thiacetazone, 
thiobenzamide, and isothionicotinamide, and thus, is probably re-
sponsible, as suggested by the observation of crossover resistance, 
for the oxidative activation of other thioamide antituberculosis 
drugs [17]. It was discovered that purified EthA displayed a re-
markably low activity with ETH. 
 Typical components of the mycobacterial cell wall are mycolic 
acids. It has been shown that the ability of mycobacteria to synthe-
size the so-called wax ester micolic acids relies on a Baeyer-
Villiger oxidation step. Hinted by the presence of a Baeyer-Villiger 
monooxygenase sequence motif in the EthA sequence, it was dis-
covered that the enzyme converts a wide range of ketones to the 
corresponding esters or lactones via a Baeyer-Villiger reaction, 
indicating that EthA represents a Baeyer-Villiger monooxygenase 
[42]. EthA is also able to catalyze enantioselective sulfoxidation of 
methyl-p-tolylsulfide [42]. Redox monitoring of the flavin cofactor 
during turnover of phenylacetone indicates that a step in the reduc-
tive half-reaction is limiting the rate of catalysis. 
 Vilchève et al. proposed the first mechanism of action of ETH, 
that is a drug activated by the monooxygenase EthA. The activated 
forms react with nicotinamide adenine dinucleotide (NAD
+
) to form 
an ETH-NAD adduct (Fig. (5)) [46]. This adduct inhibited the 
common target InhA, the NAD-dependent enoyl-ACP reductase of 
the fatty acid synthase type II system, resulting in the inhibition of 
mycolic acid biosynthesis and cell lysis. The resistance to ETH is 
associated with recessive mutations in the genes encoding the acti-
vator of the drug, EthA, which prevents drug activation. ETH resis-
tance is associated with dominant mutations in the gene encoding 
the common target of the drug, InhA, which result in target amplifi-
cation or target modification [46]. 
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 Hanoulle et al. showed that the intracellular metabolization of 
ETH strictly depends on the presence of the monooxygenase (EthA) 
and that EthA-dependent activation of ETH is coupled to a precise 
molecular sorting mechanism of the ETH metabolites [40]. The 
authors reported that substantial amounts of the ETH-treated myco-
bacteria produced the previously identified ETH metabolite 2-ethyl-
4-hydroxymethylpyridine (7, Fig. (2)), which is present exclusively 
outside of the bacteria.  
 The appearance of new data about the type of metabolite 
formed can be clarified by other research works involving the me-
tabolism of thioamides [47, 48]. Thioamide could be metabolized to 
support bacterial growth but the mechanism of nitrogen release was 
not established [47]. In another study, a bacterium was isolated for 
its ability to grow on thioacetamide as its role nitrogen source. A 
pure culture was obtained, determined to be a Ralstonia pickettii 
strain, and its mechanism of thioacetamide and thiobenzamide me-
tabolism were elucidated. It was proposed that R. pickettii degrades 
thioamides via a mechanism involving consecutive oxygenations of 
the thioamide sulphur atom [33]. Using a cell-based activation 
method, it was demonstrated that thioamides (as ETH) formed co-
valent adducts with NAD and that these adducts were tightly bind-
ing inhibitors of M. tuberculosis and M. leprae IhnA [34]. The crys-
tal structures of the inhibited M. leprae and M. tuberculosis InhA 
complexes provided the molecular details of target-drug interac-
tions. ETH-NAD showed monomolar inhibitor concentration (Ki) 
against M. tuberculosis InhA. Nishida et al. further determined the 
IC50 values from the dose-response plots of enzyme fractional activ-
ity as a function of the Ki values [35]. 
 In Fig. (6) two plausible mechanisms are represented for the 
activation of ETH. Both routes will lead to the observed ETH-NAD 
adduct, retaining a tetrahedral carbon at position 4 of the nicotina-
mide ring [37]. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Possible reaction mechanisms for the activation of ETH and the 
formation of ETH-NAD [37]. 
 Dover et al. reported that EthA, a common activator of thiocar-
bamide-containing drugs, acts on different mycobacterial targets 
[38]. This study indicated that EthA is the activator of three antitu-
berculosis drugs: ETH, thiacetazone (8, TAC, Fig. (7)) and isoxyl 
(9, ISO, Fig. (7)). 
 
Fig. (7). Structures of the thiocarbamide-containing antituberculosis drugs: 
8, thiacetazone (TAC); and 9, isoxyl (ISO). 
 
 Once activated, ETH inhibits mycolic acid biosynthesis by 
targeting InhA, which is also the primary target of activated INH (3, 
Fig. (1)). These aspects are represented in detail in Fig. (8) [38]. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Summary of the activation mechanism of the four antituberculosis 
drugs. Prodrugs get into tubercle bacilli by passive diffusion, where they are 
activated by specific proteins to a range of reactive radicals or species [38]. 
DesA3 (Rv3229c) from M. tuberculosis is a membrane-bound stearoyl 
coenzyme A 9 desaturase that reacts with the oxidoreductase Rv3230c to 
produce oleic acid.  
 
 Mycothiol (MSH) is the glutathione analogue for mycobacteria. 
Mutations in MSH biosynthetic genes have been associated with 
resistance to INH and ETH in mycobacteria. The construction of 
independent null deletion mutants for all four genes involved in the 
MSH biosynthesis pathway (MshA, MshB, MshC and MshD) 
showed different resistance to INH and ETH [49, 50]. 
 One of the most pronounced characteristics observed in the first 
MSH mutant isolated from Streptomyces strains was its >25-fold 
increase in resistance to INH (3) [51]. The MshB-deficient mutant, 
 
 
 
 
 
 
 
Fig. (5). Mechanism of action of ETH [46]. 
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which makes 5 to 10% of normal MSH levels, has been reported to 
be only slightly more resistant to INH than the wild type in a disk 
assay [52, 53], suggesting that moderate levels of MSH are suffi-
cient to confer normal sensitivity to 3. Also, enhanced resistance to 
ETH is another characteristic of the MshA-, MshB-, and MshD-
deficient mutants, with complete resistance at 50 μg/mL [52, 53]. 
The high levels of resistance of the MSH mutants to 3 and ETH 
suggest that MSH is involved in the activation of these drugs, be-
cause both 3 and ETH are prodrugs which need to be activated 
intracellularly and whose reactive groups must be unmasked before 
inhibiting their target [54]. Recently, it was demonstrated that muta-
tions in MSH biosynthesis genes may contribute to INH or ETH 
resistance across mycobacterial species, because these mutants 
showed low-level resistance to INH but were highly resistant to 
ETH [55]. The MshA, MshC, and MshB single deletion mutants 
were resistant to ETH, indicating that ETH resistance is modulate 
by the level of Msh in M. smegmatis. Surprisingly, the MsdD dele-
tion mutant lacked Msh production but was sensitive to both INH 
and ETH [56]. 
 It is important to note that in the second-line therapy for drug-
resistant tuberculosis, ETH should be administered with other drugs 
to avoid rapid development of resistance when the drug is used as 
monotherapy. The use of ETH and PTA (2, Fig. (1)) is increasing in 
MDR resistant strains M. tuberculosis. ETH is used interchangeably 
with 2 [57]. 
 With the integration of EthR, which controls the resistance of 
M. tuberculosis to ETH, into a synthetic mammalian gene network, 
Weber et al. have been able to identify the licensed food additive 2-
phenylethyl-butyrate as a potent inhibitor of EthR in M. tuberculo-
sis, which dramatically increases the sensitivity of this pathogen to 
the last-line-of-defense drug ETH and potentially to other EthA-
dependent compounds [58]. More recently, drug-like inhibitors of 
EthR were identified to boost the bioactivation of ETH [59]. These 
compounds were screened for their capacity to inhibit EthR-DNA 
interaction by cocrystallization with EthR. One of these analogs 
enabled the prepartion of a substantially reduced dose of ETH in 
order to lessen the capacity of mycobacterial load in an efficient 
manner as the conventional higher-dose used in the treatment [59]. 
Again, it was concluded that thiocarbamide-containing drugs, as 
ETH, were activated by the mycobacterial monooxygenase EthA, 
and the production of which was controlled by the transcriptional 
repressor EthR. 
 The mammalian FMOs (EC 1.14.13.8), a superfamily of flavo-
protein monooxygenases active towards a wide range of xenobiot-
ics, catalyse the oxidative metabolism of bioactive thiourea-based 
drugs [36, 60-63], and FMO1 and FMO3 have been shown in vitro 
to catalyse the oxygenation of thiacetazone (8, TAC, Fig. (8)), 
forming the same products as EtaA [62]. TAC and ETH act against 
mycobacteria in the lung, and were investigated for the ability of 
human FMO2.1 to catalyse the oxygenation of these antituberculo-
sis drugs [34]. This protein catalyzes oxygenation of both TAC and 
ETH, forming the same metabolites as those produced by human 
FMO1 and FMO3, and by the mycobacterial enzyme EthA. These 
results provide a potential explanation for some of the observed 
inter-individual differences in the efficacy and response to TAC and 
ETH, and have implications for the treatment of tuberculosis in sub-
Saharan Africa and in individuals of recent African descent [34].  
 By studying the mutations of enzymes associated to ETH me-
tabolism we can understand the resistance of the drug. Various 
mechanisms involved in mycothiol biosynsthesis were reported, 
including mutations altering EthA/EthR, InhA and its promoter, the 
NADH dehydrogenase encoded by ndh, and the MshA enzyme. 
However, the mechanism of resistance to ETH remained unknown 
for 19% of the ETH
r
 (clinical isolates: 47 ETH-resistant), highlight-
ing the complexity of the mechanisms of ETH resistance in M. 
tuberculosis [64]. 
 Carette et al. demonstrated that the inhibitory effect of highly 
diverse specific ligands of EthR can be mimicked by the mutation 
G106W [65]. This explains how two small cyclic molecules, such 
as dioxane [66], induced the same conformational state as the one 
induced with hexadecyl-octanoate [67, 68]. These results suggested 
that exploitation of deeper positions of this ligand pocket to in-
crease their affinity/specificity would be successful as long as these 
molecules interact with the upper region of the surrounding glycine 
106 [65]. Engohang-Ndong et al. reported that EthR, which en-
codes a repressor belonging to the TetR/CamR family of transcrip-
tional regulators, negatively regulates the expression of EthA [69]. 
At this point, it is possible to propose the cycle for metabolism of 
ETH (Fig. (9)), according to its active form (ETH-SO), its activator 
(EthA) and the repressor implicated in drug resistance in mycobac-
teria (EthR). 
 
Fig. (9). The ETH cycle proposed. 
 
 A biophysical study of ETH was presented recently involving 
ETH. The interaction between ETH and serum albumin was inves-
tigated employing different spectroscopic techniques [70]. The 
results revealed that the secondary structure of the protein was af-
fected upon interaction with the drug. The fluorescence results indi-
cated the presence of static quenching mechanism in the binding of 
ETH to the protein. Based on spectral data it was concluded that the 
ETH bound to side I of the protein, which is located in the hydro-
phobic pocket of subdomain IIA [70]. 
 After ionization, compounds with functional thioamide group 
exist under tautomeric equilibria [71] and, despite of that, it has 
been possible to develop new ETH derivatives, denominated by 
oxazolinyl (10, Fig (10)) and N-hydroxy-alkyl (11, Fig. (10)) [72]. 
This is an important step to fight the MDR-tuberculosis and the 
valuable contribution of new derivatives of ETH can help to under-
stand better the metabolism of the parental drug. Other advantages 
can be the association of ETH with other drugs, such as gatiflox-
acin, which in combination with ETH has great promise for the 
treatment of tuberculosis [73].  
 
Fig. (10). New ETH derivatives: 10, R=H or CH3; and 11, n=35. 
ETH-SO
EthREthA
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Site of Activation 
 The ultimate site of action of ETH is the same as the one of 
INH. Gene array studies have shown that both ETH and INH in-
duce similar patterns of protein expression [74], and mutations in 
the InhA gene give rise to resistance to both ETH and INH [45, 75]. 
In addition, it has also been shown that both activated ETH and 
PTA inhibit EtaA [37], and that the basis for the inhibition of InhA 
by ETH and PTA yields ETA-NADH and PTA-NADH adducts, 
respectively, which are similar to the adduct obtained with INH 
[37]. The formation mechanism of the activated ETH molecule is 
possible due to the formation of the S-oxide preceded by hydrolysis 
of the putative sulfinic acid to give the amide [35]. This is ex-
plained by the fact that sulfinic acid is a good leaving group and can 
be displaced by nucleophiles, whereas NAD
+
 is an electron defi-
cient ring and is highly unlikely to act as a nucleophile. Therefore, 
the sulfinic acid might undergo homolytic cleavage to give the car-
bon radical, as addition to the NAD
+
 ring followed by hydrolysis of 
the imine function [35]. Recently, by using high throughput mi-
croarray data and interactome network, Chen et al. have shown that 
the active drug-treated networks are associated with the trigger of 
fatty acid metabolism and synthesis, as well as to NADH-related 
processes, and that the efflux pumps processes appear to be the 
major mechanisms of resistance [76]. 
CONCLUSION 
 Global tuberculosis epidemic has been complicated by the re-
cent worldwide emergence of MDR strains of M. tuberculosis. Re-
cent attempts to potentiate the existing antimycobacterial activities, 
such as ETH and other drugs, have increased the possibility for 
targeting resistance which might offer a shortcut to broaden the 
chemotherapeutic options for tuberculosis treatment, thus decelerat-
ing the dissemination of drug resistant forms. ETH plays a central 
role in the treatment of patients that exhibit resistance to the front-
line drugs. This anti-tuberculosis drug is known to strongly inhibit 
mycolic acid synthesis in M. tuberculosis. As a result of the second 
oxidative cycle, the oxidation of thioamide groups in ETH produces 
sulfoxides which are converted to sulfinic acid. The sulfinic acids 
can decompose and in some cases react with NAD
+
 to generate 
adducts that reversibly inhibit cell wall synthesis in M. tuberculosis. 
In addition, it may serve as electrophilic agent that modifies pro-
teins in either the mycobacterium or in the host tissue if produced 
by host FMO enzymes. This makes ETH a molecule of great inter-
est still to fight against M tuberculosis, which can even be further 
explored in the future by combining it with other therapeutic ap-
proaches.  
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